PHARMACOKINETICS OF TROPATEPINE IN HEALTHY-VOLUNTEERS

Tropatepine is a compound with central anticholinergic properties that has been used in the treatment of neuroleptic-induced extrapyramidal syndrome. In this study, we report the plasma pharmacokinetics of trop atepine after intravenous and oral administration (20mg) in 8 healthy volunteers, after oral administration of different doses (10, 15 and 2 0mg) in 12 healthy volunteers, and following administration of multipl e dosages of the drug (20 mg/day) in 2 healthy volunteers. Pharmacokin etic parameters of tropatepine and the desmethylated active metabolite nortropatepine were estimated. Clearance following intravenous admini stration (19 +/- 4 L/h) and after multiple-dose oral administration (2 7 to 28 L/h) were stable given a bioavailability of 76.1 +/- 24%. A go od correlation was found between dose (10, 15 and 20mg) and maximum pl asma concentration (C-max) [6.5 +/- 4.5 mu g/L, 8.5 +/- 6.2 mu g/L and 18.2 +/- 8.2 mu g/L, respectively] and total quantity of tropatepine excreted in urine over a period of 120 hours (200 + 67 mu g, 254 +/- 9 3 mu g and 351 +/- 139 mu g, respectively). Such a correlation and the stable clearance confirmed a good linearity in plasma concentrations. Time to reach C-max (t(max)) was 6 to 7 hours for tropatepine and nor tropatepine. This delay and the half-life of tropatepine (around 40 ho urs) were long enough to allow daily administration. However, plasma c oncentrations varied from a C-max of 29 +/- 1.4 mu g/L to a C-min of 1 3.8 +/- 1.1 mu g/L. This doubling in concentration led to the fraction ation of the daily dose. Divisible tablets of 5mg have been prepared b y Diamant Laboratories. Since the half-life of nortropatepine is long (65.5 +/- 7.95 hours), the range of variations in plasma concentration was smaller than that of tropatepine, i.e. between a C-min of 6.5 +/- 1.5 mu g/L and a C-max of 9.5 +/- 3.2 mu g/L. Tropatepine undergoes i mportant metabolism, but nortropatepine is not the main metabolite. Af ter multiple-dose administration, the ratio of urinary excretion of no rtropatepine to tropatepine was higher (152%) than that after single-d ose administration (62%).